Key result
Mesalazine therapy for ulcerative colitis is linked to rare cardiomyopathy presenting as cardiogenic shock.
This case highlights mesalazine-induced cardiomyopathy and cardiogenic shock as a rare but serious adverse reaction in patients treated for inflammatory bowel disease.
Answers are grounded in this paper and cite their sources.
Mesalazine may rarely trigger cardiogenic shock in ulcerative colitis; this Level 5 case leaves open causality and incidence.
Five-amino salicylic acids are recommended for use in the management of inflammatory bowel disease, cardiac complications are a rare although recognised phenomenon. This report aims to highlight this serious but rare adverse reaction. We report here a case of a young man presenting with cardiogenic shock in the context of recent mesalazine treatment in severe ulcerative colitis.
No takes yet. Share an insight, caveat, or question.
Fleming et al. (2015) studied this question. Mesalazine treatment for severe ulcerative colitis was implicated in a rare but serious case of cardiomyopathy presenting as cardiogenic shock in a young male patient.
Synapse has enriched 10 related papers. Consider them for comparative context: